Ingenuity Systems Announces Renewal and Expansion of Licensing Agreement With GNF.

REDWOOD CITY, CA – JAN. 16, 2007 – Ingenuity Systems announced today that the Genomics Institute of the Novartis Research Foundation (GNF) has entered into an agreement to renew and expand the number of licenses to the Ingenuity Pathway Analysis (IPA) software for use in their research programs.

GNF has used IPA since 2003 and has cited it in published research. John Walker, Group Leader of RNA Profiling at GNF, co-authored a paper published in Chemistry and Biology titled “Purmorphamine induces osteogenesis by activation of the hedgehog-signaling pathway,” which describes the successful use of IPA to determine the mechanism of action of a biologically-active small molecule, which is a sometimes daunting task.

IPA is a software application that enables researchers to model, analyze and understand the complex biological systems at the core of life science research. IPA is deployed in all major pharmaceutical companies and hundreds of biotechnology companies and academic institutions globally. It supports analysis of all high throughput analysis platforms and is used in virtually all areas of drug discovery and development from target identification and validation to biomarkers, predictive toxicology, and pharmacogenomics.

IPA is available as a web-delivered, hosted, or deployed solution. Fully functional complimentary trials are available at

About Ingenuity Systems®

Ingenuity enables researchers to model, analyze and understand complex biological systems foundational to human health and disease. The Ingenuity products include pathways analysis software and knowledge bases for biologists and bioinformaticians, and enterprise knowledge management infrastructure, content and services for leading pharmaceutical and biotech companies. Ingenuity was founded in 1998 and is headquartered in Redwood City, California with offices in Germany, Switzerland, France, the United Kingdom, and Japan.